Single entry point insulin delivery pod device to be developed
A type 1 diabetes charity is to help develop a single pod Automated Insulin Delivery (AID) device with a single entry skin point, it has been announced.
JDRF has announced its partnership with SFC Fluidics, Inc. (SFC), a medical technology company to create a pod device, providing people with type 1 diabetes the ability to accurately measure their blood glucose and deliver background insulin automatically.
The technology will combine a continuous glucose monitor, insulin pump and computer program in one device which can be disposed of every three days. Not only that, but unlike current pump and CGM technologies which pierce the skin at two locations, the innovative invention will only pierce the skin in one place.
Angela Wipperman, JDRF’s senior research communications manager, said: “We are committed to advancing the development of automated insulin delivery systems that will reduce the burden of dealing with type 1 diabetes day to day, and improve glucose control. Our partnership with SFC Fluidics will help the development of devices that are easier to wear, therefore making diabetes therapies less intrusive for daily use and giving everyone with type 1 greater choice.
“We know people with type 1 diabetes, especially children and young adults, can find existing technology cumbersome and painful to insert. A device that would require piercing the skin in just one place would be a positive change for those already using wearable devices, and could help more people who could benefit from this technology consider it as an option.”
Jaime Giraldo, JDRF’s program scientist in research, said: “We are proud to be supporting SFC as part of our effort to advance the development of next-generation automated insulin delivery systems, to offer greater choice to people with T1D, and to lessen the burden of living with this disease while we search for a cure.
“By funding the development of miniaturized devices that are easier to wear and include algorithms for automation, it is our goal to make diabetes therapies less intrusive for those who must use them daily to live.”
Anthony Cruz, chief executive officer (CEO) of SFC Fluidics, said: “SFC’s unique pumping technology allows for an integrated AID system that will offer people with type 1 diabetes an improved lifestyle. With our partnership with JDRF, we will bring new and innovative solutions to the diabetes community.”